0.22

4.71% 0.0099

Pre-market: .22

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $0.22, with a volume of 13.16M. It is up +4.71% in the last 24 hours and down -39.34% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Previous Close:

$0.2101

Open:

$0.219

24h Volume:

13.16M

Relative Volume:

0.77

Market Cap:

$51.63M

Revenue:

$48.47M

Net Income/Loss:

$-170.37M

P/E Ratio:

-0.2934

EPS:

-0.7499

Net Cash Flow:

$-171.35M

1W Performance:

+10.50%

1M Performance:

-39.34%

6M Performance:

-93.41%

1Y Performance:

-81.67%

1-Day Range:

$0.2112

$0.2388

1-Week Range:

$0.19

$0.24

52-Week Range:

$0.1626

$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(858) 684-1300

Address

3115 MERRYFIELD ROW, SAN DIEGO, CA

Employee

162

Twitter

@GossamerBio

Next Earnings Date

2026-05-21

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	0.22	49.31M	48.47M	-170.37M	-171.35M	-0.7499
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-24-26	Downgrade	Barclays	Overweight → Equal Weight
Feb-24-26	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-24-26	Downgrade	Wedbush	Outperform → Neutral
Jan-28-26	Initiated	Barclays	Overweight
Sep-10-25	Upgrade	UBS	Neutral → Buy
Jul-14-25	Initiated	Scotiabank	Sector Outperform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

03:42 AM

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

03:42 AM

May 26, 2026

GOSS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus

May 26, 2026

Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. - GlobeNewswire

May 26, 2026

Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors - GlobeNewswire

May 26, 2026

GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities LawsuitContact The Gross Law Firm - PR Newswire

May 26, 2026

GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS – Company AnnouncementFT.com - Financial Times

May 26, 2026

May 25, 2026

Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

May 25, 2026

GOSS Stockholders Have Opportunity to Lead Gossamer Bio, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

May 25, 2026

May 24, 2026

GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. ... - Caledonian Record

May 24, 2026

GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW - GlobeNewswire

May 24, 2026

GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile

May 24, 2026

May 23, 2026

GOSS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile

May 23, 2026